Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11948008 | 0.91 | LRRK2 (0.38) | CYP2C9CYP2C19MKNK2LRRK2GRM5 | |
| SCHEMBL13561387 | 0.91 | CYP2C9 (0.46) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL4098258 | 0.90 | CYP2C9 (0.43) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL13561278 | 0.89 | CYP2C9 (0.45) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL4100668 | 0.89 | CYP2C9 (0.51) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL4112035 | 0.89 | CYP2C9 (0.44) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL4116031 | 0.88 | CYP2C9 (0.53) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL4106026 | 0.87 | CYP2C9 (0.49) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL13561386 | 0.84 | CYP2C9 (0.49) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 | |
| SCHEMBL11947385 | 0.83 | ROCK2 (0.38) | CYP2C9CYP2C19KCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2220091-B1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | CYP2C9 2156/4885CYP2C19 1979/4885KCNH2 4781/4885 |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | CYP2C9 2156/4885CYP2C19 1979/4885KCNH2 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.